Last reviewed · How we verify
BDA MDI
BDA MDI is a medication that works by delivering a specific dose of a therapeutic agent directly to the lungs.
BDA MDI is a medication that works by delivering a specific dose of a therapeutic agent directly to the lungs. Used for Asthma.
At a glance
| Generic name | BDA MDI |
|---|---|
| Sponsor | Bond Avillion 2 Development LP |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action for BDA MDI is not well-documented, but it is believed to involve the direct delivery of a therapeutic agent to the lungs, where it can exert its effects.
Approved indications
- Asthma
Common side effects
- Cough
- Wheezing
Key clinical trials
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (PHASE3)
- Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (PHASE4)
- A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (PHASE3)
- A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma (PHASE3)
- Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. (PHASE1)
- A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (PHASE3)
- Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BDA MDI CI brief — competitive landscape report
- BDA MDI updates RSS · CI watch RSS
- Bond Avillion 2 Development LP portfolio CI